BackZentalis Pharmaceuticals Overview
Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Target Price

Analysts' average 12-month price target for Zentalis Pharmaceuticals is $5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.6

Average Target Price

$5.0092.3% upside

1 analysts in the last 4 months

High: $5 | Low: $5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Morgan Stanley$592.3% upsideOpen
2026-05-22H.C. WainwrightAndrew Fein$10284.6% upsideOpen
2026-04-10Guggenheim$10284.6% upsideOpen
2025-11-11Leerink PartnersAndrew Berens$223.1% downsideOpen
2024-06-18JefferiesAkash Tewari$6130.8% upsideOpen
2024-06-18Morgan StanleyMatthew Harrison$8207.7% upsideOpen
2024-06-18Stifel NicolausBradley Canino$10284.6% upsideOpen
2024-06-18WedbushRobert Driscoll$453.8% upsideOpen
2024-05-07Stifel NicolausBradley Canino$321130.8% upsideOpen
2022-11-14Wedbush$321130.8% upsideOpen
2022-11-11Morgan Stanley$552015.4% upsideOpen
2022-11-11Guggenheim$28976.9% upsideOpen
2022-08-10Leerink Partners$421515.4% upsideOpen
2022-08-10H.C. Wainwright$552015.4% upsideOpen
2022-07-29Stifel NicolausBradley Canino$702592.3% upsideOpen

Zentalis Pharmaceuticals (ZNTL) FAQ

Zentalis Pharmaceuticals (ZNTL) currently reports a target price of $5. Use the charts on this page to explore Zentalis Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Zentalis Pharmaceuticals is $5, about 92.3% upside from the current share price of $2.6. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $5, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zentalis Pharmaceuticals, and consider following ZNTL for alerts when major investors trade the stock.

Zentalis Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $5. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZNTL with unrelated industries.